GLAXO PLANNING LONG-TERM SEREVENT POSTMARKETING STUDY IN UP TO 30,000
Executive Summary
GLAXO PLANNING LONG-TERM SEREVENT POSTMARKETING STUDY IN UP TO 30,000 patients to explore safety concerns related to the use of the drug in target populations. The firm's commitment to conducting the large trim comes in the wake of reports of deaths in elderly patients who may have taken the long-acting beta-2 agonist inappropriately for acute asthma attacks.